U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498933) titled 'FAP-targeted PET/NIR in Lung Malignant Tumors' on March 23.
Brief Summary: Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localizati...